ABL Diagnostics

Research ABL Diagnostics (ABLD.PA) on Bullrun: market cap EUR 38.89M, P/E 40.3, dividend yield 4.4%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 38.89M; P/E is 40.3; dividend yield is 4.4%.

Peer valuation comparison

Latest P/E is 40.33x versus a Healthcare sector median of 23.44x (72.1% above).

Latest dividend yield is 4.44% versus a Healthcare sector median of 2.1% (111.4% above).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 6.95MEUR 986.70KEUR 714.76K95.3%n/aEUR 1.08MEUR 2.25MEUR 7.63M
FY2024EUR 5.33MEUR 285.17K-EUR 2.32M90.7%0.02EUR 468.78KEUR 2.55MEUR 7.49M
FY2023EUR 5.61MEUR 54.36Kn/a86.9%0EUR 2.22MEUR 3.47MEUR 6.77M
FY2022EUR 8.75MEUR 1.11Mn/a95.1%0.07EUR 1.01MEUR 2.66MEUR 6.75M
FY2021n/an/a-EUR 56.69Kn/a0.13n/an/an/a

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-09-05EUR 38.89M40.34.6%0.11

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.11 EUR, yield 4.4%.

YearDividends/share
FY20250.05 EUR

About ABL Diagnostics

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is ABL Diagnostics's market cap?

ABL Diagnostics's market capitalization is EUR 38.89M.

What is ABL Diagnostics's P/E ratio?

ABL Diagnostics's price-to-earnings (P/E) ratio is 40.3.

Does ABL Diagnostics pay a dividend?

ABL Diagnostics has a dividend yield of 4.4%.

What does ABL Diagnostics do?

ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally.